<VariationArchive VariationID="2945246" VariationName="NM_016169.4(SUFU):c.1246_1249dup (p.Phe417fs)" VariationType="Duplication" Accession="VCV002945246" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2024-02-29" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3105017" VariationID="2945246">
      <GeneList>
        <Gene Symbol="SUFU" FullName="SUFU negative regulator of hedgehog signaling" GeneID="51684" HGNC_ID="HGNC:16466" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>10q24.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102502819" stop="102633535" display_start="102502819" display_stop="102633535" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="104263718" stop="104393213" display_start="104263718" display_stop="104393213" Strand="+" />
          </Location>
          <OMIM>607035</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_016169.4(SUFU):c.1246_1249dup (p.Phe417fs)</Name>
      <CanonicalSPDI>NC_000010.11:102617377:GCCT:GCCTGCCT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>10q24.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102617377" stop="102617378" display_start="102617377" display_stop="102617378" variantLength="4" positionVCF="102617377" referenceAlleleVCF="C" alternateAlleleVCF="CGCCT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="104377134" stop="104377135" display_start="104377134" display_stop="104377135" variantLength="4" positionVCF="104377134" referenceAlleleVCF="C" alternateAlleleVCF="CGCCT" />
      </Location>
      <ProteinChange>F417fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.10" sequenceAccession="NC_000010" sequenceVersion="10" change="g.104377135_104377138dup" Assembly="GRCh37">
            <Expression>NC_000010.10:g.104377135_104377138dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.11" sequenceAccession="NC_000010" sequenceVersion="11" change="g.102617378_102617381dup" Assembly="GRCh38">
            <Expression>NC_000010.11:g.102617378_102617381dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_021338.1" sequenceAccession="NG_021338" sequenceVersion="1" change="g.118417_118420dup">
            <Expression>NG_021338.1:g.118417_118420dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001178133.2" sequenceAccession="NM_001178133" sequenceVersion="2" change="c.1246_1249dup">
            <Expression>NM_001178133.2:c.1246_1249dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001171604.1" sequenceAccession="NP_001171604" sequenceVersion="1" change="p.Phe417fs">
            <Expression>NP_001171604.1:p.Phe417fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016169.4" sequenceAccession="NM_016169" sequenceVersion="4" change="c.1246_1249dup" MANESelect="true">
            <Expression>NM_016169.4:c.1246_1249dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_057253.2" sequenceAccession="NP_057253" sequenceVersion="2" change="p.Phe417fs">
            <Expression>NP_057253.2:p.Phe417fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_521" sequenceAccession="LRG_521">
            <Expression>LRG_521:g.118417_118420dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_521t1" sequenceAccession="LRG_521t1">
            <Expression>LRG_521t1:c.1246_1249dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_521p1" sequenceAccession="LRG_521p1" change="p.Phe417Cysfs">
            <Expression>LRG_521p1:p.Phe417Cysfs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_016169.4(SUFU):c.1246_1249dup (p.Phe417fs) AND multiple conditions" Accession="RCV003800900" Version="1">
        <ClassifiedConditionList TraitSetID="23440">
          <ClassifiedCondition DB="MedGen" ID="C0004779">Gorlin syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0025149">Medulloblastoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-03-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-03-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-29" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22508808</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25403219</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33024317</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="23440" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="381" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Basal cell nevus syndrome</ElementValue>
                <XRef ID="UWMG_1854558" DB="CSER _CC_NCGL, University of Washington" />
                <XRef Type="Phenotypic series" ID="PS109400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gorlin syndrome</ElementValue>
                <XRef ID="69408002" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7166" />
                <XRef ID="7166" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of life, and/or basal cell carcinomas (BCCs) usually from the third decade onward. Approximately 60% of individuals have a recognizable appearance with macrocephaly, frontal bossing, coarse facial features, and facial milia. Most individuals have skeletal anomalies (e.g., bifid ribs, wedge-shaped vertebrae). Ectopic calcification, particularly in the falx, is present in more than 90% of affected individuals by age 20 years. Cardiac and ovarian fibromas occur in approximately 2% and 20% of individuals respectively. Approximately 5% of all children with NBCCS develop medulloblastoma (primitive neuroectodermal tumor), generally the desmoplastic subtype. The risk of developing medulloblastoma is substantially higher in individuals with an SUFU pathogenic variant (33%) than in those with a PTCH1 pathogenic variant (&lt;2%). Peak incidence is at age one to two years. Life expectancy in NBCCS is not significantly different from average.</Attribute>
                <XRef ID="NBK1151" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301330</ID>
                <ID Source="BookShelf">NBK1151</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="PubMed">21304560</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="377" DB="Orphanet" />
              <XRef ID="C0004779" DB="MedGen" />
              <XRef ID="MONDO:0007187" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS109400" DB="OMIM" />
            </Trait>
            <Trait ID="2738" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MEDULLOBLASTOMA PREDISPOSITION SYNDROME</ElementValue>
                <XRef Type="MIM" ID="155255" DB="OMIM" />
                <XRef Type="Allelic variant" ID="612250.0002" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Medulloblastoma</ElementValue>
                <XRef ID="Medulloblastoma/4552" DB="Genetic Alliance" />
                <XRef ID="HP:0002885" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007959" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medulloblastoma, somatic</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MDB</ElementValue>
                <XRef Type="MIM" ID="155255" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7005" />
                <XRef ID="7005" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®) Central Nervous System Cancers, 2023</CitationText>
              </Citation>
              <XRef ID="616" DB="Orphanet" />
              <XRef ID="C0025149" DB="MedGen" />
              <XRef ID="D008527" DB="MeSH" />
              <XRef ID="MONDO:0007959" DB="MONDO" />
              <XRef Type="MIM" ID="155255" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002885" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8548416" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2024-02-28">
        <ClinVarSubmissionID localKey="18665427|MedGen:C0004779;C0025149" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004592537" DateUpdated="2024-02-28" DateCreated="2024-02-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22508808</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25403219</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33024317</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant has not been reported in the literature in individuals affected with SUFU-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe417Cysfs*5) in the SUFU gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SUFU are known to be pathogenic (PMID: 22508808, 25403219, 33024317).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SUFU" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000010.10:g.104377134_104377135insGCCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0004779" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0025149" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8548416" TraitType="Disease" MappingType="XRef" MappingValue="C0004779" MappingRef="MedGen">
        <MedGen CUI="C0004779" Name="Gorlin syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8548416" TraitType="Disease" MappingType="XRef" MappingValue="C0025149" MappingRef="MedGen">
        <MedGen CUI="C0025149" Name="Medulloblastoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

